February 2019 – Femeda Ltd wins Partnership with Academia Award!
Femeda Ltd scooped the ‘Partnership with Academic Award’ at last night’s Medilink Healthcare Business Awards 2019.
Femeda picked up the award following a highly successful few months since the online launch of Pelviva, an innovative, disposable muscle re-trainer that treats bladder leakage in women. Pelviva is clinically effective, discreet and easy to use, with studies showing that after 12 weeks of regularly using Pelviva, 84% of women reported improved bladder control.
The Femeda project began life as a MIMIT clinical unmet need and MIMIT’s Director, Professor Jackie Oldham, continues to work extremely closely with the team and the project.
Full information on Femeda and Pelviva can be found here
MEDILINK Healthcare Business Awards 2019
Femeda Ltd launched ‘Pelviva’, a life-changing technological breakthrough for the treatment of weak pelvic floor muscles that cause bladder leaks in women, following an unmet need disclosure to MIMIT in 2007. Pelviva is now available to purchase online and has already won Product of the Year at the prestigious Bionow Awards in 2018.
Lucid Group Ltd continues to develop the design of a novel ‘one stop’ neurophysiological tool enabling accurate, non-volitional assessment of anorectal function in patients with, or predisposed to, faecal incontinence. This originated as a MIMIT unmet clinical need in 2010.
The MEDILINK awards take place this Wednesday evening at The Hilton, Leeds.
The full shortlist for all awards can be found here
NIHR i4i Product Development Award Win
A huge congratulations to one of our MIMIT Ambassadors Brendan McGrath and team, who have been awarded the NIHR (National Institute for Health Research) i4i Product Development Award worth £641,003 for Above Cuff Vocalisation (ACV), a MIMIT supported project that was matched with a solution at a MIMIT forum.
As a bit of background, tracheostomies are small plastic tubes inserted into the neck. These ‘artificial airways’ are used most commonly in the Intensive Care Unit (ICU) for patients who are weak, or who need breathing support from a ventilator. Some Head & Neck surgical operations also need a tracheostomy. Around 20,000 new tracheostomies are inserted in the UK each year, with around two-thirds in ICU patients.
Patients report that when they wake up with a tracheostomy, the worst thing is not being able to speak. Tubes have a balloon or cuff which ‘seals off’ the upper airway (nose and mouth), meaning that gas breathed in and out does not flow through the larynx (voice-box). Patients can be fully awake and yet unable to speak, lasting for days or weeks. Other communication is made worse by weakness, making it hard for patients to tell staff or loved ones how they are feeling, causing stress and worry and makes caring for patients more difficult.
Our research shows that if the voice-box is not used for several days, the muscles become weak. As patients start to recover, the weakened voice-box makes swallowing, coughing, talking and getting off the ventilator more difficult and the process takes longer. Our research demonstrated that making the voice-box work by getting patients talking earlier had a positive effect on voice-box function, as well as giving patients back the gift of speech.
The ACV project aims to get patients with new tracheostomies talking earlier in their treatment, by developing a safe and effective system to deliver gas flows ‘above the cuff’ of the tube, and out of the mouth via the voice-box.
ACV can only currently be delivered using a continuous flow of cold, dry gas, without safety features. The first two years of this new project involves designing and testing a new product to safely deliver warm, moist gas for ACV, delivered when the patient wants to speak, and ensuring patient comfort.
The final year of the project involves conducting a study using the device developed and comparing it to tracheostomy patients who do not use it. Brendan and the team will work with patients, doctors, nurses and speech and language therapists to record the effect that the device has on:
- Talking: can patients talk earlier and with a better voice?
- Eating: can patients swallow earlier?
- Stress and worry
- Time spent in ICU or in hospital
By the end of this project, the team aim to have developed a carefully tested (clinically validated) prototype medical device that is able to safely and effectively deliver ACV, helping patients communicate and speeding up their recovery.
Further information on the technique can be found here.
MIMIT IS 10
On Wednesday 7th November 2018, MIMIT celebrated its 10 year anniversary in Manchester’s landmark Citylabs.
Welcoming an audience of clinicians, academics, industry leads, policy makers, collaborators and supporters, Professor Jackie Oldham (MIMIT Director) showcased the incredible impact that MIMIT has spearheaded over the last decade, including £31.2m of commercial funding leverage, 5 licenses, 100 academic publications, 4 spin out companies, 83 jobs created and 5 million patient benefits in Greater Manchester already (with many more to come).
MIMIT clinical Ambassadors John New (Consultant Diabetologist, Salford Royal Foundation Trust and North West e-Health Director Salford Lung Study) and Peter Alexander (Consultant in Anaesthesia and Intensive Care Medicine, Manchester Foundation Trust) joined MIMIT academic Ambassadors Emma Stanmore (Senior Lecturer, School of Health Sciences, University of Manchester) and Alex Casson (Senior Lecturer in Sensing, Imaging and Signal Processing, University of Manchester), discussing why they are part of MIMIT, the integral relationships the partnership provides and the collaboration, opportunities and successes that have arisen as a result.
MIMIT was also supported by video messages from the original CIMIT founders, John Parrish and Colleen Kigin, showcasing just how far the model has come.
Guests also had an opportunity to view finalised projects that originated as MIMIT unmet needs, such as Pelviva (a pelvic floor trainer for the treatment of bladder leakage in women).
Finally, the evening culminated in thanks to Professor Oldham and the late Keith Chantler for their vision, as-well as MIMIT’s collaborators, ambassadors, investors and supporters.
PELVIVA SHORTLISTED FOR ‘PRODUCT OF THE YEAR’
Pelviva (a disposable, clinically effective, discreet and easy-to-use pelvic floor muscle re-trainer for the treatment of bladder leakage in women) has been shortlisted for ‘Product of the Year’ at the prestigious Bionow Awards 2018.
The Pelviva project originated as a MIMIT unmet need for female bladder leakage and the subsequent research and evolved partnerships facilitated by MIMIT resulted in a spin out company for the Pelviva product.
One in three women experience bladder leaks but after 12 weeks of regularly using Pelviva, 84% of women reported improved bladder control (as part of a single blind randomised control trial).